Share-based Payment Arrangement, Expense of DiaMedica Therapeutics Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
DiaMedica Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,016,000, a 80% increase year-over-year.
  • DiaMedica Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,243,000, a 66% increase year-over-year.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,085,000, a 24% increase from 2023.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,683,000, a 12% increase from 2022.
  • DiaMedica Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,502,000, a 3.6% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

DiaMedica Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,243,000 $1,016,000 +$451,000 +80% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $2,792,000 $771,000 +$328,000 +74% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $2,464,000 $867,000 +$379,000 +78% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $2,085,000 $589,000 +$133,000 +29% 01 Oct 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
Q3 2024 $1,952,000 $565,000 +$140,000 +33% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $1,812,000 $443,000 +$63,000 +17% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $1,749,000 $488,000 +$66,000 +16% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,683,000 $456,000 +$45,000 +11% 01 Oct 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $1,638,000 $425,000 +$7,000 +1.7% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $1,631,000 $380,000 +$15,000 +4.1% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $1,616,000 $422,000 +$114,000 +37% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $1,502,000 $411,000 +$113,000 +38% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $1,389,000 $418,000 +$115,000 +38% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $1,274,000 $365,000 -$81,000 -18% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $1,355,000 $308,000 -$203,000 -40% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $1,558,000 $298,000 -$208,000 -41% 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $1,766,000 $303,000 -$205,000 -40% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $1,971,000 $446,000 +$10,000 +2.3% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,961,000 $511,000 +$118,000 +30% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $1,843,000 $506,000 +$105,000 +26% 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q3 2020 $1,738,000 $508,000 +$57,000 +13% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $1,681,000 $436,000 +$254,000 +140% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $1,427,000 $393,000 +$263,000 +202% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $1,164,000 $401,000 +$336,000 +517% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2021 2020 FY
Q3 2019 $828,000 $451,000 +$341,000 +310% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $487,000 $182,000 -$110,000 -38% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $597,000 $130,000 -$23,000 -15% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q4 2018 $620,000 $65,000 01 Oct 2018 31 Dec 2018 10-K 23 Mar 2020 2019 FY
Q3 2018 $110,000 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $292,000 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2
Q1 2018 $153,000 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1

DiaMedica Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,085,000 +$402,000 +24% 01 Jan 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
2023 $1,683,000 +$181,000 +12% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
2022 $1,502,000 -$56,000 -3.6% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $1,558,000 -$285,000 -15% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $1,843,000 +$679,000 +58% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2022 2021 FY
2019 $1,164,000 +$544,000 +88% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2021 2020 FY
2018 $620,000 +$211,000 +52% 01 Jan 2018 31 Dec 2018 10-K 23 Mar 2020 2019 FY
2017 $409,000 01 Jan 2017 31 Dec 2017 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.